Sol-Gel Technologies Ltd.
Close on Oct 19, 2026
- Market cap
- $212.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2025 Ended Jun 30, 2025 | Aug 15, 2025 | Before market open | $17.20M | $4.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 16, 2024 | Before market open | $5.40M | $0.07 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | Before market open | $594.00K | $0.22 | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 4, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 30, 2022 | Before market open | – | – | – |
Press releases
Announcements Sol-Gel Technologies filed with the SEC
Dear Sol-Gel Technologies Ltd. Shareholders:
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
to Host KOL Investor Day for SGT-610 on October 14, 2026
EX-99.1 to Form 6-K
Phase 3 Clinical Trial of SGT-610 in
EX-99.1 to Form 6-K
Results and Provides Corporate Updates
EX-99.1 to Form 6-K
Investments in Corporate bonds rated A or higher.
EX-99.2 to Form 6-K
First Quarter 2026 Financial Results and Provides Corporate Updates
EX-99.1 to Form 6-K
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed
EX-99.1 to Form 6-K
Sol-Gel Provides Update Following Unblinding of
EX-99.1 to Form 6-K
Sol-Gel Reports Third Quarter 2025 Financial Results
EX-99.1 to Form 6-K
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
Sol-Gel Announces Health Canada Approval of EPSOLAY®
EX-99.1 to Form 6-K
Sol-Gel Reports Second Quarter 2025 Financial
EX-99.1 to Form 6-K
Sol-Gel Reports First Quarter 2025 Results
EX-99.1 to Form 6-K
Sol-Gel Announces Reverse Share Split
EX-99.1 to Form 6-K
Sol-Gel and Mayne Pharma Announce the Purchase
EX-99.1 to Form 6-K
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above
EX-99.2 to Form 6-K
Sol-Gel Announces 180-Day Extension to Regain Compliance with
EX-99.1 to Form 6-K
Sol-Gel Reports Third Quarter 2024 Financial Results
EX-99.1 to Form 6-K
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
VOTE BY INTERNET - www.proxyvote.com or scan the QR
EX-99.2 to Form 6-K
Sol-Gel Reports Second Quarter 2024 Financial
EX-99.1 to Form 6-K
Investments in Corporate bonds rated A or higher.
EX-99.2 to Form 6-K
SOL-GEL ANNOUNCES THE SIGNING OF SIX EXCLUSIVE LICENSE AGREEMENTS TO
EX-99.1 to Form 6-K
Sol-Gel Technologies Announces Management Realignment
EX-99.1 to Form 6-K
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above
EX-99.3 to Form 6-K
Sol-Gel Technologies Announces Management Realignment
EX-99.1 to Form 6-K
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above
EX-99.3 to Form 6-K
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
EX-99.1 to Form 6-K
Sol-Gel Reports First Quarter 2024 Financial Results and Provides
EX-99.1 to Form 6-K
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to
EX-99.1 to Form 6-K
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
EX-99.1 to Form 6-K
Sol-Gel Reports Full-Year 2023 Financial Results and
EX-99.1 to Form 6-K
IMPORTANT NOTICE TO SHAREHOLDERS WHO ARE UNITED STATES PERSONS
EX-99.1 to Form 6-K
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K